Immunohistochemical analysis of samples showed an increased amount of phosphorylated ERK1/2 in NRASQ61-mutated melanoma upon 2-DG treatment, together with areas that stained positive for cleaved-caspase 3 surrounding necrotic tissue in tumors treated with the combination, in which intact cells stained negative for p-ERK1/2 (Fig. 8e). This evidence concerns the gene MAPK3 and melanoma.